

**SCHEDULE OF INVESTMENTS**

March 31, 2020

**BIOTECHNOLOGY FUND**

	SHARES	VALUE		SHARES	VALUE
<b>COMMON STOCKS<sup>†</sup> - 99.6%</b>					
<b>BIOTECHNOLOGY - 77.2%</b>					
Gilead Sciences, Inc.	163,732	\$ 12,240,604			
Amgen, Inc.	58,142	11,787,128			
Regeneron Pharmaceuticals, Inc.*	20,112	9,820,488			
Vertex Pharmaceuticals, Inc.*	40,445	9,623,888			
Biogen, Inc.*	28,829	9,120,919			
Illumina, Inc.*	24,935	6,810,247			
Seattle Genetics, Inc.*	44,885	5,178,831			
Alexion Pharmaceuticals, Inc.*	51,833	4,654,085			
BioMarin Pharmaceutical, Inc.*	53,836	4,549,142			
Incyte Corp.*	57,026	4,176,014			
Alnylam Pharmaceuticals, Inc.*	35,690	3,884,856			
ACADIA Pharmaceuticals, Inc.*	69,528	2,937,558			
Guardant Health, Inc.*	39,438	2,744,885			
Ionis Pharmaceuticals, Inc.*	56,232	2,658,649			
Exact Sciences Corp.*	44,657	2,590,106			
Exelixis, Inc.*	148,806	2,562,439			
United Therapeutics Corp.*	26,008	2,466,209			
Ultragenyx Pharmaceutical, Inc.*	43,750	1,943,813			
Nektar Therapeutics*	104,961	1,873,554			
PTC Therapeutics, Inc.*	41,710	1,860,683			
FibroGen, Inc.*	50,727	1,762,763			
Blueprint Medicines Corp.*	29,512	1,725,862			
Mirati Therapeutics, Inc.*	21,283	1,636,024			
Immunomedics, Inc.*	120,092	1,618,840			
BeiGene Ltd. ADR*	12,580	1,548,724			
Bluebird Bio, Inc.*	28,921	1,329,209			
Arrowhead Pharmaceuticals, Inc.*	44,717	1,286,508			
Intercept Pharmaceuticals, Inc.*	19,573	1,232,316			
Ligand Pharmaceuticals, Inc. — Class B* <sup>1</sup>	14,791	1,075,602			
Myriad Genetics, Inc.*	60,813	870,234			
Sage Therapeutics, Inc.*	20,116	577,732			
Amarin Corporation plc ADR* <sup>1</sup>	130,623	522,492			
<b>Total Biotechnology</b>		<u>118,670,404</u>			
<b>PHARMACEUTICALS - 19.2%</b>					
AbbVie, Inc.	151,830	11,567,928			
Neurocrine Biosciences, Inc.*	34,429	2,979,830			
Mylan N.V.*	188,846	2,815,694			
Sarepta Therapeutics, Inc.*	28,749	2,812,227			
PRA Health Sciences, Inc.*	28,111	2,334,337			
Jazz Pharmaceuticals plc*	18,477	1,842,896			
Global Blood Therapeutics, Inc.*	32,973	1,684,591			
Agios Pharmaceuticals, Inc.*	43,958	1,559,630			
Alkermes plc*	106,006	1,528,606			
Portola Pharmaceuticals, Inc.*	63,270	451,115			
<b>Total Pharmaceuticals</b>		<u>29,576,854</u>			
<b>HEALTHCARE-PRODUCTS - 1.9%</b>					
Bio-Techne Corp.	15,528	2,944,419			
<b>HEALTHCARE-SERVICES - 1.3%</b>					
Syneos Health, Inc.*	49,240	1,941,041			
<b>Total Common Stocks</b>		<u>153,132,718</u>			
(Cost \$83,320,381)					
			<b>RIGHTS<sup>†††</sup> - 0.0%</b>		
			<b>BIOTECHNOLOGY - 0.0%</b>		
			Clinical Data, Inc.* <sup>2</sup>	24,000	\$ —
			<b>Total Rights</b>		
			(Cost \$—)		—
				<b>FACE</b>	
				<b>AMOUNT</b>	
			<b>REPURCHASE AGREEMENTS<sup>††3</sup> - 0.4%</b>		
			J.P. Morgan Securities LLC		
			issued 03/31/20 at 0.01%		
			due 04/01/20	\$ 466,498	466,498
			BofA Securities, Inc.		
			issued 03/31/20 at 0.00%		
			due 04/01/20	179,422	179,422
			<b>Total Repurchase Agreements</b>		
			(Cost \$645,920)		645,920
				<b>SHARES</b>	
			<b>SECURITIES LENDING COLLATERAL<sup>†4</sup> - 1.2%</b>		
			<b>Money Market Fund</b>		
			First American Government		
			Obligations Fund — Class Z, 0.39% <sup>5</sup>	1,830,522	1,830,522
			<b>Total Securities Lending Collateral</b>		
			(Cost \$1,830,522)		1,830,522
			<b>Total Investments - 101.2%</b>		
			(Cost \$85,796,823)		\$ 155,609,160
			<b>Other Assets &amp; Liabilities, net - (1.2)%</b>		(1,792,478)
			<b>Total Net Assets - 100.0%</b>		\$ 153,816,682

**BIOTECHNOLOGY FUND**

\* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

††† Value determined based on Level 3 inputs.

<sup>1</sup> All or a portion of this security is on loan at March 31, 2020.

<sup>2</sup> Security was fair valued by the Valuation Committee at March 31, 2020. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.

<sup>3</sup> Repurchase Agreements.

<sup>4</sup> Securities lending collateral.

<sup>5</sup> Rate indicated is the 7-day yield as of March 31, 2020.

ADR — American Depositary Receipt

plc — Public Limited Company